HC Wainwright Reaffirms Buy Rating for UroGen Pharma (NASDAQ:URGN)

HC Wainwright reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research note published on Thursday morning, Marketbeat.com reports. The brokerage currently has a $54.00 price objective on the stock.

Separately, Oppenheimer lowered their price target on shares of UroGen Pharma from $35.00 to $34.00 and set an outperform rating on the stock in a report on Friday, March 15th.

UroGen Pharma Price Performance

URGN stock opened at $14.26 on Thursday. The firm’s fifty day simple moving average is $16.30 and its 200-day simple moving average is $14.59. The company has a market capitalization of $334.40 million, a P/E ratio of -3.82 and a beta of 1.07. UroGen Pharma has a 12 month low of $8.69 and a 12 month high of $24.13.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.05). The firm had revenue of $23.53 million for the quarter, compared to analyst estimates of $22.30 million. As a group, sell-side analysts forecast that UroGen Pharma will post -3.59 earnings per share for the current year.

Insider Buying and Selling

In related news, General Counsel Jason Drew Smith sold 4,993 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total transaction of $78,589.82. Following the sale, the general counsel now directly owns 18,824 shares of the company’s stock, valued at $296,289.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other UroGen Pharma news, insider Mark Schoenberg sold 12,000 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $14.05, for a total transaction of $168,600.00. Following the completion of the transaction, the insider now directly owns 139,437 shares in the company, valued at $1,959,089.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Jason Drew Smith sold 4,993 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $15.74, for a total transaction of $78,589.82. Following the transaction, the general counsel now owns 18,824 shares of the company’s stock, valued at $296,289.76. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,782 shares of company stock valued at $306,829. Corporate insiders own 11.13% of the company’s stock.

Hedge Funds Weigh In On UroGen Pharma

Large investors have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC acquired a new position in UroGen Pharma during the fourth quarter worth $27,000. Acadian Asset Management LLC acquired a new stake in shares of UroGen Pharma in the first quarter valued at about $42,000. Legal & General Group Plc raised its position in shares of UroGen Pharma by 34.6% in the fourth quarter. Legal & General Group Plc now owns 2,868 shares of the company’s stock valued at $43,000 after buying an additional 738 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of UroGen Pharma in the third quarter valued at about $53,000. Finally, BNP Paribas Arbitrage SNC raised its position in shares of UroGen Pharma by 2,782.5% in the second quarter. BNP Paribas Arbitrage SNC now owns 5,102 shares of the company’s stock valued at $53,000 after buying an additional 4,925 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.